Literature DB >> 23574133

Abiraterone in metastatic prostate cancer.

Charles J Ryan, Arturo Molina, Thomas Griffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23574133     DOI： 10.1056/NEJMc1301594

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  23 in total

1.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

2.  Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Authors:  Qiang Wu; Manish Kohli; H Robert Bergen; John C Cheville; R Jeffrey Karnes; Hong Cao; Charles Y F Young; Donald J Tindall; Mark A McNiven; Krishna Vanaja Donkena
Journal:  Mol Cancer Ther       Date:  2014-03-27       Impact factor: 6.261

3.  Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells via hydrogen peroxide (H2O2)-mediated oxidative stress.

Authors:  Somaiah Chinnapaka; Guoxing Zheng; Aoshuang Chen; Gnanasekar Munirathinam
Journal:  Free Radic Biol Med       Date:  2019-08-22       Impact factor: 7.376

4.  Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.

Authors:  Jie Li; Anju Karki; Kurt B Hodges; Nihal Ahmad; Amina Zoubeidi; Klaus Strebhardt; Timothy L Ratliff; Stephen F Konieczny; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2015-10-05       Impact factor: 4.272

5.  Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.

Authors:  Elgene Lim; Min Ni; Shiliang Cao; Aditi Hazra; Rulla M Tamimi; Myles Brown
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01

6.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

7.  Hormone whodunit: clues for solving the case of intratumor androgen production.

Authors:  Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2014-08-18       Impact factor: 12.531

8.  Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Authors:  Styliani Karanika; Theodoros Karantanos; Likun Li; Jianxiang Wang; Sanghee Park; Guang Yang; Xuemei Zuo; Jian H Song; Sankar N Maity; Ganiraju C Manyam; Bradley Broom; Ana M Aparicio; Gary E Gallick; Patricia Troncoso; Paul G Corn; Nora Navone; Wei Zhang; Shuhua Li; Timothy C Thompson
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

Review 9.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.

Authors:  Rosie Elizabeth Ann Gutteridge; Mary Ann Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2016-06-21       Impact factor: 6.261

10.  Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.

Authors:  Francesco Massari; Chiara Ciccarese; Anna Caliò; Enrico Munari; Luca Cima; Antonio Benito Porcaro; Giovanni Novella; Walter Artibani; Teodoro Sava; Albino Eccher; Claudio Ghimenton; Francesco Bertoldo; Aldo Scarpa; Nicola Sperandio; Camillo Porta; Vincenzo Bronte; Marco Chilosi; Giuseppe Bogina; Giuseppe Zamboni; Giampaolo Tortora; Hemamali Samaratunga; Guido Martignoni; Matteo Brunelli
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.